ISIS 301012 subcutaneous: Phase II data

In a Phase II trial in 48 patients already receiving high doses of lipid-lowering drugs, the 2 higher doses of ISIS 301012 met the primary endpoint of a significant reduction in baseline LDL-C vs. pla...